

IMMUNOBIOLOGY

Altered natural killer cell subset homeostasis and defective chemotactic responses in paroxysmal nocturnal hemoglobinuria

Yasser M. El-Sherbiny,¹⁻³ Richard J. Kelly,¹ Anita Hill,¹ Gina M. Doody,¹ Peter Hillmen,¹ and Graham P. Cook¹¹Leeds Institute of Cancer and Pathology, and ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom;and ³Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt

Key Points

- Paroxysmal nocturnal hemoglobinuria identifies a role for GPI-linked proteins in the homeostasis of human NK cell subsets.
- GPI-deficient NK cells exhibit impaired chemotactic responses.

In paroxysmal nocturnal hemoglobinuria (PNH), hematopoietic cells lacking glycosylphosphatidylinositol (GPI)-linked proteins on their surface (GPI^{neg}) exist alongside normal (GPI⁺) cells. Analysis of natural killer (NK) cell subsets in 47 PNH patients revealed that the ratio of CD56^{bright}:CD56^{dim} NK cells differed in the GPI⁺ and GPI^{neg} populations, with GPI^{neg}CD56^{bright} NK cells significantly more abundant in peripheral blood than their normal GPI⁺ counterparts. Indeed, GPI⁺CD56^{bright} NK cells were not detected in the peripheral blood of some patients, suggesting their trafficking to a niche unavailable to the GPI^{neg}CD56^{bright} NK cell population. Defective cellular trafficking in this disease was supported by findings showing differential chemokine receptor expression between GPI⁺ and GPI^{neg} NK cells and impaired stromal cell–derived factor 1 (SDF-1)–induced chemotaxis of GPI^{neg} NK cells. Our results indicate a role for GPI-linked proteins in NK cell subset homeostasis and suggest that differential

chemokine responses might contribute to the balance of GPI⁺ and GPI^{neg} populations in this disease. (*Blood*. 2013;122(11):1887-1890)

Introduction

The glycosylphosphatidylinositol (GPI) anchor secures numerous proteins to the cell surface.¹ In paroxysmal nocturnal hemoglobinuria (PNH), there is expansion of hematopoietic stem cells (HSCs) harboring a somatic mutation in the X-linked *PIGA* gene, disrupting a key step in GPI anchor biosynthesis.^{2,3} These mutant HSCs generate substantial populations of mature blood cells lacking GPI-linked proteins; red blood cells and platelets lacking the GPI-linked complement protectors CD55 and CD59 are highly susceptible to complement-mediated lysis, resulting in many of the clinical features of PNH.^{2,3} Accordingly, inhibiting the formation of the complement membrane attack complex using a humanized anti-C5 antibody (eculizumab) is an effective therapy.^{2,3}

Human natural killer (NK) cells are classified into 2 main subsets.⁴ The weakly cytotoxic CD56^{bright} cells constitute 10% of peripheral blood NK cells and are the likely precursors of the highly cytotoxic CD56^{dim} cells, which constitute the remaining 90% of peripheral NK cells in the blood. However, CD56^{bright} NK cells express lymph node homing molecules, and the ratio of CD56^{dim}:CD56^{bright} cells is reversed in secondary lymphoid tissue.^{5,6} We analyzed NK cells from 47 PNH patients and identified a role for GPI-linked molecules in NK cell chemotactic responses and the homeostasis of NK cell subsets.

Study design

Peripheral blood samples were collected, after informed consent in accordance with the Declaration of Helsinki, from 47 PNH patients (32 receiving

eculizumab; supplemental Figure 1, available on the *Blood* Web site) attending the PNH National Service clinic in Leeds, United Kingdom. The study was approved by the Leeds Teaching Hospitals National Health Service Trust ethical review board. Cells were stained with antibodies defining NK cells (CD56+CD3^{neg}) and GPI-linked molecules (CD48, CD59, CD160; see supplemental Methods). Discrimination of GPI⁺ and GPI^{neg} NK cells was also performed using fluorescent aerolysin, a modified bacterial toxin that binds to intact GPI anchors.⁷ For migration assays, NK cells (purified by indirect selection) were applied to 5-μM membrane transwells (Corning) and allowed to migrate in response to 100 nM stromal cell–derived factor 1 (SDF-1; R&D Systems). The GPI⁺:GPI^{neg} NK cell ratio was analyzed in the input and migrated populations by flow cytometry. Further details are provided in supplemental Methods.

Results and discussion

The GPI^{neg} NK cells in PNH patients lacked cell surface expression of the GPI-linked molecules CD48, CD59, and CD160 (Figure 1A). GPI⁺ and GPI^{neg} populations of CD56^{dim} and CD56^{bright} NK cell subsets were detectable in the majority of patients (Figure 1B; supplemental Figure 1). However, in 10 PNH patients, the GPI⁺CD56^{bright} NK cells made up less than 0.02% of the total GPI⁺ cells (Figure 1B; supplemental Figure 1). This was not associated with eculizumab treatment, and 4 patients analyzed on multiple occasions revealed this to be a stable phenotype (Figure 1B; supplemental Figures 1-2). CD56^{bright} NK cells differentiate into CD56^{dim} NK cells,⁹⁻¹¹ and we reasoned that GPI⁺CD56^{bright} NK

Submitted June 7, 2013; accepted July 7, 2013. Prepublished online as *Blood* First Edition paper, July 23, 2013; DOI 10.1182/blood-2013-06-507574.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2013 by The American Society of Hematology




Figure 1. Altered NK cell subset homeostasis in PNH. (A) Cell surface expression of the GPI-linked proteins CD48, CD59, and CD160 on the NK cells (gated on CD56+CD3^{neg} cells) of a healthy control (HC) and a PNH patient. Staining with fluorescent aerolysin (FLAER) demarcates GPI+ from GPI^{neg} cells. (B) CD56^{bright} and CD56^{dim} NK cell subsets present in the peripheral blood of PNH patients (plots gated on CD56+CD3^{neg} cells). The top 2 rows show 3 patients with all 4 subsets of NK cells (denoted p1.number), and the bottom 2 rows show 3 patients in which the GPI+CD56^{bright} NK cells made up less than 0.02% of the total GPI+ NK cells (denoted p2.number). The 4 subsets of NK cells are indicated in different colors, according to the key. NK cells from p2.10 were analyzed on 3 occasions; the first 2 visits are shown here, and the third visit, together with sequential analysis of 3 other patients, is shown in supplemental Figure 2. Across the cohort of 47 patients, the size of the GPI^{neg} NK cell population varied from ~1% to ~99% of the total NK cells (supplemental Figure 1), in agreement with previous findings.⁸ An "E" after the patient number indicates the patient was receiving eculizumab at the time of analysis. (C) Frequency of CD56^{bright} NK cells as a percentage of total GPI^{neg} or total GPI+ NK cells compared with healthy controls. *P* values (calculated using the Mann-Whitney nonparametric test) are shown for statistically different data.

cells must be present in these individuals to generate the GPI+CD56^{dim} population. Furthermore, GPI+CD56^{bright} NK cells have the normal, not the GPI-deficient, phenotype. We speculated that the GPI+CD56^{bright} NK cells were present in all PNH patients but that GPI+CD56^{bright} and GPI^{neg}CD56^{bright} NK cells were differentially distributed between the peripheral blood and other tissues. Indeed, CD56^{bright} NK cells have lymph node homing properties, and inflammation results in their loss from the periphery.^{12,13} We suggest that the GPI^{neg}CD56^{bright} NK cells are outcompeted by the normal GPI+CD56^{bright} NK cells for entrance to (or occupancy of) a niche such as the secondary lymphoid tissue. Such competition would reduce the occupancy of this niche by GPI^{neg}CD56^{bright} NK cells, resulting in their enrichment in peripheral blood. Accordingly, analysis of the entire PNH cohort revealed that GPI^{neg}CD56^{bright} NK cells were significantly more abundant in peripheral blood compared with their GPI+ counterparts and with the CD56^{bright} NK cells from healthy donors (Figure 1C).

The importance of chemokines in leukocyte trafficking suggests that impaired chemotactic responses might underlie altered NK cell subset distribution in PNH. The expression of chemokine receptors

by NK cells is complex,^{14,15} and it is difficult to perform chemotaxis assays on the small numbers of CD56^{bright} cells available from these patients. We therefore analyzed the responses of GPI+ and GPI^{neg} NK cell populations to SDF-1/CXCL12, the CXCR4 ligand. CXCR4 is expressed by the majority of peripheral blood NK cells, aiding these studies.^{14,15} Treatment of NK cells with phosphatidylinositol-specific phospholipase C (PI-PLC) removed GPI anchor-linked proteins but left CXCR4 expression intact. These PI-PLC treated NK cells exhibited significantly reduced migration in response to SDF-1, whereas sialidase treatment had no effect (Figure 2A-B). This suggested that GPI-deficient NK cells have impaired chemotactic responses. We repeated the SDF-1 migration assays using NK cells from 6 PNH patients in which all 4 GPI+/GPI^{neg} and CD56^{bright}/CD56^{dim} subsets were present in peripheral blood. We analyzed the ratio of GPI+:GPI^{neg} NK cells in the starting population and in the migrating cells and found that the SDF-1-induced migration significantly enriched the GPI+ NK cells (Figure 2C-D).

These results reveal that optimal chemotactic responses require GPI-linked molecules: GPI-linked proteins are abundant in lipid rafts, *PIGA* mutations disrupt raft formation, and CXCR4 requires




Figure 2. Defective chemotaxis in GPI^{neg} NK cells. (A) Cell surface expression of CD48, CXCR4, and CD15s on NK92 cells, with and without enzyme treatment. PI-PLC hydrolyses GPI anchors (removing CD48 but preserving CXCR4 and CD15s), whereas sialidase treatment leaves CD48 and CXCR4 expression intact but removes sialic acid and destroys the CD15s antigen. (B) Migration of enzyme-treated NK92 cells (left) or primary NK cells (right) to SDF-1. Cells were treated with either sialidase (S) or PI-PLC (P) or were left untreated (U). The data were analyzed using the Mann-Whitney nonparametric test. SDF-1 induced migration by a factor of 4 over media lacking the chemokine (data not shown). (C) Migration of NK cells from 6 PNH patients in response to SDF-1. Pie charts show the percentage of GPI+ (black slice) and GPI^{neg} (white slice) NK cells applied to the assay (top; input population) and those that migrated in response to the chemokine (bottom; migrated population). Patient p1.38 was an addition to the 47 patients in the cohort shown. (D) Analysis of migration of NK cells from the 6 PNH patients according to the size of the GPI+ population in the input and migrated fractions. The *P* value was calculated using the Wilcoxon matched-pairs signed rank test. (E) CXCR4, CCR7, and CXCR3 expression on the GPI+ and GPI^{neg} NK cells of 7 PNH patients. The lines link the NK cells from a particular patient. The data show the percentage of NK cells expressing these chemokine receptors (determined by flow cytometry) as a fraction of the total GPI+ or GPI^{neg} NK cell population. Analysis of the expression of these molecules on the CD56^{dim} and CD56^{bright} NK cell subsets is shown in supplemental Figure 3. *P* values were calculated using Wilcoxon matched-pairs signed rank test.

incorporation into these structures for optimal activity.¹⁶⁻¹⁸ In GPI^{neg} NK cells, SDF-1 responses may be impaired because of the redistribution of CXCR4 to membrane microdomains less able to support receptor signaling or into a local membrane environment that alters CXCR4 conformation.¹⁷ Impaired SDF-1 responses were not caused by defective CXCR4 expression, as GPI^{neg} NK cells expressed significantly higher levels of cell surface CXCR4 compared with their GPI+ counterparts (Figure 2E; supplemental Figure 3). Increased chemokine receptor expression has previously been reported in GPI-deficient cells,¹⁹ and we also found elevated expression of CXCR3 and CCR7 on GPI^{neg} NK cells (Figure 2E; supplemental Figure 3). Indeed, CCR7 is preferentially expressed by CD56^{bright} NK cells, and this receptor exhibited greater expression on the GPI^{neg}CD56^{bright} NK cells (supplemental Figure 3). Elevated receptor expression may reflect *in vivo* selection, whereby GPI^{neg} NK cells respond to chemokines only if they express high levels of the receptor, favoring their survival. Alternatively, defective chemokine receptor activity may prevent activation-induced internalization in GPI^{neg} NK cells, increasing cell surface expression.²⁰

Why the GPI+CD56^{bright} NK cells were undetectable in the blood of just a fifth of PNH patients is unclear. However, NK subset homeostasis is regulated by both environmental (eg, infection/inflammation⁹⁻¹³) and genetic factors,²¹ and separating their respective contributions within the confines of the rare PNH phenotype represents a considerable challenge. Defective SDF-1/CXCR4 activity cannot itself account for the altered subset homeostasis we observed in the patients, but it does highlight defective chemotaxis in PNH. Several models have been proposed to account for the abundance of GPI^{neg} cells in PNH, focusing on the maintenance and expansion of GPI^{neg} HSC.^{3,22,23} Our results indicate that the balance of GPI+ and GPI^{neg} cells within a particular hematopoietic lineage is governed not only by the abundance of GPI^{neg} HSC but also by *in vivo* processes operating on mature cells. GPI-linked molecules are known to play a role in cellular trafficking and homeostasis of other hematopoietic cell types.^{24,25} Furthermore, GPI^{neg}CD34+ cells exhibit enhanced SDF-1 chemotaxis but reduced adhesion to SDF-1.²³ Our results appear contradictory to these findings, but such differences may be explained by the presence of

cell-type-specific factors that regulate chemokine receptor activity.²⁰ Despite their differences, our data, and those of Ratajczak et al,²³ reveal that differential chemotactic responses of GPI+ and GPI^{neg} cells result in unequal competition for a particular niche, contributing to the balance and persistence of GPI+ and GPI^{neg} cells in PNH.

Acknowledgments

We are grateful to other members of our laboratory for technical advice and assistance and to Alan Melcher and Pam Jones for encouragement.

References

1. Paulick MG, Bertozzi CR. The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. *Biochemistry*. 2008;47(27):6991-7000.
2. Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. *Blood*. 2009;113(26):6522-6527.
3. Pu JJ, Brodsky RA. Paroxysmal nocturnal hemoglobinuria from bench to bedside. *Clin Transl Sci*. 2011;4(3):219-224.
4. Caligiuri MA. Human natural killer cells. *Blood*. 2008;112(3):461-469.
5. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA. CD56^{bright} natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. *Blood*. 2003;101(8):3052-3057.
6. Ferlazzo G, Thomas D, Lin SL, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. *J Immunol*. 2004;172(3):1455-1462.
7. Brodsky RA, Mukhina GL, Li S, Nelson KL, Chiurazzi PL, Buckley JT, Borowitz MJ. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. *Am J Clin Pathol*. 2000;114(3):459-466.
8. Richards SJ, Norfolk DR, Swirsky DM, Hillmen P. Lymphocyte subset analysis and glycosylphosphatidylinositol phenotype in patients with paroxysmal nocturnal hemoglobinuria. *Blood*. 1998;92(5):1799-1806.
9. Chan A, Hong DL, Atzberger A, et al. CD56^{bright} human NK cells differentiate into CD56^{dim} cells: role of contact with peripheral fibroblasts. *J Immunol*. 2007;179(1):89-94.
10. Huntington ND, Legrand N, Alves NL, et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. *J Exp Med*. 2009;206(1):25-34.
11. Yu J, Mao HC, Wei M, et al. CD94 surface density identifies a functional intermediary between the CD56^{bright} and CD56^{dim} human NK-cell subsets. *Blood*. 2010;115(2):274-281.
12. Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF. CD56^{bright} NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. *J Immunol*. 2004;173(10):6418-6426.
13. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, Grom AA. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. *Arthritis Res Ther*. 2005;7(1):R30-R37.
14. Campbell JJ, Qin S, Unutmaz D, et al. Unique subpopulations of CD56⁺ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. *J Immunol*. 2001;166(11):6477-6482.
15. Berahovich RD, Lai NL, Wei Z, Lanier LL, Schall TJ. Evidence for NK cell subsets based on chemokine receptor expression. *J Immunol*. 2006;177(11):7833-7840.
16. Nguyen DH, Taub D. CXCR4 function requires membrane cholesterol: implications for HIV infection. *J Immunol*. 2002;168(8):4121-4126.
17. Wysoczynski M, Reca R, Ratajczak J, et al. Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient. *Blood*. 2005;105(1):40-48.
18. Szpurka H, Schade AE, Jankowska AM, Maciejewski JP. Altered lipid raft composition and defective cell death signal transduction in glycosylphosphatidylinositol anchor-deficient PIG-A mutant cells. *Br J Haematol*. 2008;142(3):413-422.
19. Alfinito F, Ruggiero G, Sica M, et al. Eculizumab treatment modifies the immune profile of PNH patients. *Immunobiology*. 2012;217(7):698-703.
20. Bennett LD, Fox JM, Signorel N. Mechanisms regulating chemokine receptor activity. *Immunology*. 2011;134(3):246-256.
21. Xia Z, Liu Q, Berger CT, et al. A 17q12 allele is associated with altered NK cell subsets and function. *J Immunol*. 2012;188(7):3315-3322.
22. Dingli D, Luzzatto L, Pacheco JM. Neutral evolution in paroxysmal nocturnal hemoglobinuria. *Proc Natl Acad Sci USA*. 2008;105(47):18496-18500.
23. Ratajczak J, Kucia M, Mierzejewska K, et al. A novel view of paroxysmal nocturnal hemoglobinuria pathogenesis: more motile PNH hematopoietic stem/progenitor cells displace normal HSPCs from their niches in bone marrow due to defective adhesion, enhanced migration and mobilization in response to erythrocyte-released sphingosine-1 phosphate gradient. *Leukemia*. 2012;26(7):1722-1725.
24. Funaro A, Ortolan E, Ferranti B, Gargiulo L, Notaro R, Luzzatto L, Malavasi F. CD157 is an important mediator of neutrophil adhesion and migration. *Blood*. 2004;104(13):4269-4278.
25. Takedachi M, Qu D, Ebisuno Y, et al. CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes. *J Immunol*. 2008;180(9):6288-6296.

Authorship

Contribution: R.J.K., A.H., and P.H. manage the PNH clinic and recruited the patient cohort; Y.M.E.-S. performed the experimental work; Y.M.E.-S., G.M.D., and G.P.C. analyzed the data; G.P.C. and Y.M.E.-S. designed the study; and G.P.C. wrote the article with input from all authors.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Graham Cook; Leeds Institute of Cancer and Pathology, University of Leeds, Wellcome Brenner Building, St James's University Hospital, Leeds LS9 7TF, UK; e-mail: g.p.cook@leeds.ac.uk.